



New-to-market drug list

New, FDA-approved prescription drugs will be considered non-covered for most benefits and must go through an evaluation period while being reviewed by the Wellmark Pharmacy & Therapeutics (P&T) Committee to determine coverage. The following drugs are awaiting review by the P&T Committee (Generics are in *italics*. Brand names are CAPITALIZED)

AQVESME™ (mitapivat)
AVLAYAH™ - tildenafil fumarate
AVTOZMA® (tocilizumab subcutaneous)
EXDENSUR™ (depemokimab-ulaa)
ICOTYDE™ (icotrokinra)
LEROCHOI® (lerodalcibep-liga)
LOARGYS® (pegzilarginase-nbln)
LIFYORLI™ - relacorilant pak
MIDAZOLAM AUTO-INJECTOR
MYQORZO™ (aficamten)
OMLONTI® (omidenepeg)
ONTRALFY™ (tizanidine oral solution)
ORLADEYO® (berotralstat pellet)
QIVIGY® (immune globulin intravenous, human-kthm)
WEGOVY® (semaglutide oral)
WEGOVY® HD (semaglutide)
YARTEMLEA® (narsoplimab-wuug)
YUVIWEL® (navepegritide)
ZYCUBO® (copper histidinate)